253 related articles for article (PubMed ID: 17470527)
1. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
3. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
[TBL] [Abstract][Full Text] [Related]
4. Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans.
Sakuda S; Akabane T; Teramura T
Xenobiotica; 2006 Apr; 36(4):331-40. PubMed ID: 16684712
[TBL] [Abstract][Full Text] [Related]
5. [Drug metabolism in the small intestine--the significance for biological availability].
Andersen VC; Sonne J
Ugeskr Laeger; 2000 May; 162(22):3215-9. PubMed ID: 10850220
[TBL] [Abstract][Full Text] [Related]
6. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
7. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
8. Toxicokinetics of bisphenol A in rats, monkeys and chimpanzees by the LC-MS/MS method.
Tominaga T; Negishi T; Hirooka H; Miyachi A; Inoue A; Hayasaka I; Yoshikawa Y
Toxicology; 2006 Sep; 226(2-3):208-17. PubMed ID: 16914249
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
Ogasawara A; Kume T; Kazama E
Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
[TBL] [Abstract][Full Text] [Related]
10. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
11. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
[TBL] [Abstract][Full Text] [Related]
12. Characterization of gastrointestinal drug absorption in cynomolgus monkeys.
Takahashi M; Washio T; Suzuki N; Igeta K; Fujii Y; Hayashi M; Shirasaka Y; Yamashita S
Mol Pharm; 2008; 5(2):340-8. PubMed ID: 18247527
[TBL] [Abstract][Full Text] [Related]
13. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
14. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
[TBL] [Abstract][Full Text] [Related]
15. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
Zhang W; Tan TM; Lim LY
Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
[TBL] [Abstract][Full Text] [Related]
17. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.
Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
J Pharm Pharmacol; 2004 Oct; 56(10):1259-66. PubMed ID: 15482640
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
19. Analysis and prediction of absorption profile including hepatic first-pass metabolism of N-methyltyramine, a potent stimulant of gastrin release present in beer, after oral ingestion in rats by gastrointestinal-transit-absorption model.
Kimura T; Iwasaki N; Yokoe JI; Haruta S; Yokoo Y; Ogawara KI; Higaki K
Drug Metab Dispos; 2000 May; 28(5):577-81. PubMed ID: 10772638
[TBL] [Abstract][Full Text] [Related]
20. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.
Liu YT; Hao HP; Xie HG; Lai L; Wang Q; Liu CX; Wang GJ
Drug Metab Dispos; 2010 Oct; 38(10):1779-84. PubMed ID: 20634337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
